Category - Feature

Feature

Comera working to transform biologics to SQ injections from IV delivery

Comera Life Sciences (NASDAQ:CMRA) is using a proprietary excipient formulation platform, known as SQore, to potentially transform intravenous (IV) biologics into subcutaneous (SQ) versions that patients can self...

November 1, 2022

Feature

Atossa Therapeutics pivots inhalation therapy from COVID-19 to oncology

With widespread availability of SARS-CoV-2 vaccines and other therapies now approved to treat COVID-19, Atossa Therapeutics (NASDAQ:ATOS) has pivoted development of its AT-H201 inhalation therapy to cancer patients with...

October 25, 2022

Feature

OpSens SavvyWire tackling cardiology with advanced optical devices

With last month’s FDA clearance of the SavvyWire transcatheter aortic valve replacement (TAVR) guidewire, OpSens (TSX:OPS; OTCQX:OPSSF) is bringing a new concept to interventional cardiology and the delivery of new...

October 18, 2022

Feature

VoxNeuro is giving the brain a voice through cognitive health assessment

VoxNeuro’s software as a medical device (SaMD) is transforming cognitive health assessment as it pushes the boundaries of our understanding of the brain to improve decision-making by clinicians and patients.

October 11, 2022

Feature

Sigyn Therapeutics outlines first-in-human clinical strategy for its novel blood purification technology

Sigyn Therapeutics (OTCQB:SIGY) has transitioned its Sigyn Therapy blood-purification device from conceptual design two years ago to preparing to initiate its first-in-human studies in end-stage renal disease patients...

October 4, 2022

Feature

Kiora Pharma eyes novel approach to vision restoration in retinitis pigmentosa

Kiora Pharmaceuticals (NASDAQ:KPRX) expects to release Phase 1b interim data at the beginning of 2023 from its flagship intravitreal injection to potentially restore vision in patients with retinitis pigmentosa, a rare...

September 27, 2022

Feature

Blue Water Vaccines designing vaccines against infectious diseases

Blue Water Vaccines (NASDAQ:BWV) is building an early-stage pipeline of six transformational vaccine candidates targeting important infectious diseases, including inner ear infections, influenza, norovirus, rotavirus...

September 20, 2022

Feature

SAB Biotherapeutics advancing new class of immunotherapeutic antibodies

SAB Biotherapeutics (NASDAQ:SABS) is developing its novel DiversitAb platform to produce a new class of specifically targeted, high-potency, fully-human polyclonal antibodies, without the need for human donors.

September 13, 2022

Feature

Ensysce Biosciences’ transformative chemistry targeting drug safety and performance

Ensysce Biosciences (NASDAQ:ENSC) is developing next-generation opioid products with its platform of two proprietary technologies to reduce abuse and overdose while relieving suffering for people with severe pain and...

September 6, 2022

Feature

Talking VR and mental health with Foretell Reality

As general manager for Foretell Reality and VP product for parent, Glimpse Group (NASDAQ:VRAR), a company seeking to unlock the benefits of virtual and augmented reality, Dror Goldberg was introduced to VR in its early...

August 23, 2022

Category - Feature

Comera working to transform biologics to SQ injections from IV delivery

Atossa Therapeutics pivots inhalation therapy from COVID-19 to oncology

OpSens SavvyWire tackling cardiology with advanced optical devices

VoxNeuro is giving the brain a voice through cognitive health assessment

Sigyn Therapeutics outlines first-in-human clinical strategy for its novel blood purification technology

Kiora Pharma eyes novel approach to vision restoration in retinitis pigmentosa

Blue Water Vaccines designing vaccines against infectious diseases

SAB Biotherapeutics advancing new class of immunotherapeutic antibodies

Ensysce Biosciences’ transformative chemistry targeting drug safety and performance

Talking VR and mental health with Foretell Reality

General

More